Diabetes Assays (In Vitro Diagnostics) - Global Market Analysis and Forecast Model

Diabetes Assays (In Vitro Diagnostics)-Global Market Analysis and Forecast Model

Summary

Diabetes Assays (In Vitro Diagnostics)-Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

Diabetes is one of the most common endocrine diseases, with approximately 425 million adults (20-79 years) suffering from this disease, worldwide. Diabetes mellitus refers to a group of long-lasting health conditions, which affect how blood glucose is used within the body, due to an inability to either produce or response effectively to insulin. A substantial proportion of diabetes patients are undiagnosed.

Specifically, the international diabetes federation (IDF) estimates that almost half (49.7%) of adults suffering from diabetes are unaware of their disease. Similarly, the world health organization (WHO) predicts that 24-62% of people with diabetes are undiagnosed and/or untreated.

Diabetes Assays are performed to diagnose individuals that are at higher risk of developing the disease. There are four major types of diabetes that arise due to different causes; however, all lead to hyperglycemia. They are known as type I, type II, gestational diabetes mellitus and diabetes due to other causes. Tests that are performed to diagnosis diabetes include glycated hemoglobin (HbA1c) assays, fasting glucose assays, c-peptide assays and insulin assays.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market Model

Currently marketed Diabetes Assays and evolving competitive landscape-

- Insightful review of the key industry trends.

- Annualized total Diabetes Assays market revenue by segment and market outlooks from 2015-2028.

- Granular data on total procedures, units, average selling prices and market values by segment.

Global, Regional and Country level market specific insights-

- Qualitative market specific information is available with global trends further broken down into regional trends. In addition GlobalData analysts provide unique country specific insights on the market.

- SWOT analysis for the market.

- Competitive dynamics insights and trends provided for the overall market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

- Country specific overview of the healthcare system.

- Country specific reimbursement policies.

- Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Abbott Laboratories, ALPCO Diagnostics, Danaher Corp (Beckman Coulter Inc), Bio-Rad Laboratories Inc, DiaSorin SpA, Ortho-Clinical Diagnostics Inc, PTS Diagnostics, Danaher Corp, F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Tosoh Corp, EKF-diagnostic GmbH and Others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for-

- CMO executives who must have deep understanding of the Diabetes Assays marketplace to make strategic planning and investment decisions.

- Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.

- Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to buy

The model will enable you to-

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving Diabetes Assays market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Diabetes Assays market in the future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Track device sales in the global and country-specific Diabetes Assays market from 2015-2028.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.